1. Show article details.

    Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

    GlobeNewswire – 10:02 AM ET 06/25/2022

    NEW YORK and MAINZ, GERMANY, JUNE 25, 2022 — Pfizer Inc. and BioNTech SE (BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern.

  2. Show article details.

    Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

    Business Wire – 10:00 AM ET 06/25/2022

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern.

  3. Show article details.

    The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial

    Benzinga – 9:08 AM ET 06/24/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The European Union has recommended expanded conditional approval of Novavax Inc's  Nuvaxovid COVID-19 vaccine for adolescents ages 12-17. Separately, the Taiwan Food and Drug Administration has granted emergency use authorization for the Nuvaxovid COVID-19 vaccine in individuals ages 18 and over.

  4. Show article details.

    BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug

    Benzinga – 2:42 PM ET 06/23/2022

    BioNTech received Priority Medicines designation from the European Medicines Agency for its product candidate BNT211 in the third- or later-line treatment of testicular germ cell tumors.

  5. Show article details.

    BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

    GlobeNewswire – 11:00 AM ET 06/23/2022

    MAINZ, Germany, June 23, 2022 – BioNTech SE (BNTX) today announced that that the European Medicines Agency has granted Priority Medicines designation to BioNTech’s fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors. “Patients with relapsed or treatment refractory testicular cancers have a poor prognosis with limited remaining treatment options.

  6. Show article details.

    BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa

    GlobeNewswire – 6:00 AM ET 06/23/2022

    MAINZ, Germany and KIGALI, Rwanda, June 23, 2022 – BioNTech SE (BNTX) has reached the next milestone in the establishment of scalable mRNA vaccine production in Africa on its planned schedule. During the event in Kigali, BioNTech provided an update on the joint establishment of mRNA manufacturing facilities and the development plans for BioNTech’s malaria vaccine candidates.

  7. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:30 PM ET 06/22/2022

      On Wednesday, 329 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Wednesday: Be sure to monitor Benzinga for the news traders need!

  8. Show article details.

    BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations

    GlobeNewswire – 11:30 AM ET 06/20/2022

    MAINZ, Germany, June 20, 2022 -- BioNTech SE (BNTX) will host the first edition of the Company’s Innovation Series on Wednesday, June 29th, 2022. Investors and the interested public are invited to join a webcast with investment analysts at 8:00 a.m. EDT. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

  9. Show article details.

    BioNTech Whale Trades Spotted

    Benzinga – 4:58 PM ET 06/17/2022

    A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech we detected 14 strange trades. If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.

  10. Show article details.

    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

    Benzinga – 11:18 AM ET 06/17/2022

    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

  11. Show article details.

    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

    Business Wire – 9:24 AM ET 06/17/2022

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced the U.S. Food and Drug Administration granted emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age. This press release features multimedia.

  12. Show article details.

    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

    GlobeNewswire – 9:22 AM ET 06/17/2022

    NEW YORK and MAINZ, GERMANY, June 17, 2022 — Pfizer Inc. and BioNTech SE (BNTX) today announced the U.S. Food and Drug Administration granted emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age.

  13. Show article details.

    Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot

    Benzinga – 12:53 PM ET 06/16/2022

    Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot

  14. Show article details.

    The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

    Benzinga – 10:09 AM ET 06/16/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of amending the emergency use authorization for Moderna Inc's  and Pfizer Inc /BioNTech SE  COVID-19 vaccines for children as young as six months through five years old.

  15. Show article details.

    FDA Committee Backs Pfizer, Moderna COVID-19 Vaccines For Toddlers, Youngest Children

    Benzinga – 7:20 AM ET 06/16/2022

    The FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of amending the emergency use authorization for Moderna Inc's  and Pfizer Inc  / BioNTech SE  COVID-19 vaccines for children as young as six months till five years.

  16. Show article details.

    The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data

    Benzinga – 8:49 AM ET 06/15/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Pfizer Inc  shared additional data from the Phase 2/3 EPIC-SR study of Paxlovid in patients at standard risk of developing severe COVID-19. An updated analysis from 1,153 patients showed a non-significant 51% relative risk reduction.

  17. Show article details.

    Morning Brief: Top Financial Stories Dominating on Wednesday, June 15

    Benzinga – 8:17 AM ET 06/15/2022

    Reuters Warner Bros Discovery To Undergo Major Global Ad Sales Team Restructuring Biden Questions Oil Companies On Lack Of Gasoline Amid Increasing Prices iQIYI Shares Trade Lower On Reports Of Possible Stake Sale Over 100 CEOs Including Alphabet, Amazon, Microsoft Press For China Competition Bill L3Harris Technologies Eyes Israeli Spyware Firm NSO Qualcomm Wins EU Antitrust Lawsuit Which Has...

  18. Show article details.

    FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

    Benzinga – 7:19 AM ET 06/15/2022

    FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

  19. Show article details.

    EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters

    Benzinga – 1:28 PM ET 06/14/2022

    EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters

  20. Show article details.

    Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters

    Benzinga – 1:11 PM ET 06/14/2022

    Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters

Page:

Today's and Upcoming Events

  • Aug
    08

    BNTX to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • Jun
    02

    BNTX ex-Dividend for $2.13 on 06/02/2022

    • Announce Date: 04/27/2022
    • Record Date: 06/03/2022
    • Pay Date: 06/17/2022
  • May
    09

    BNTX announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.